Insider Trading : Fri 5/12/23

Notable purchases -- CEO adds to NRDS; notable sales -- 10% owner active in WW

Buyers:

• BFH 10% owner Turtle Creek bought 190,000 shares at $25.27 - $26.87 worth ~$5.0 mln.
• CODI 10% owner bought 34,796 shares at $18.74 - $18.85 worth ~$654K.
• COIN Director bought 810,000 shares at $59.92 - $63.74 worth ~$50.0 mln.
• CPE Director bought 50,000 shares at $30.24 - $31.63 worth ~$1.5 mln.
• NRDS CEO bought 30,838 shares at $8.35 - $8.39 worth ~$258K.
• PACK CEO and Executive Chairman and one (1) Director bought a total of 116,500 shares at $2.85 - $3.30 worth ~$347K.
• SNEX Head-Retail & Foreign Exchange bought 3,000 shares at ~$84.1766 worth ~$253K.
• TFIN Director bought 9,995 shares at $47.64 - $48.80 worth ~$479K.

Sellers:

• AGNC Director, Executive Chair sold 500,000 shares at $9.25 - $9.35 worth ~$4.7 mln.
• APO 10% owner sold 572,051 shares at $62.50 - $64.70 worth ~$36.3 mln.
• AVT Director sold 72,851 shares at $41.65 - $41.93 worth ~$3.0 mln.
• CORT Chief Business Officer sold 44,000 shares at $23.81 - $24.16 worth ~$1.1 mln.
• EME EVP - Shared Services sold 13,462 shares at $165.00 - $167.73 worth ~$2.2 mln.
• JPM President & COO, CEO CIB sold 113,640 shares at ~$135.9274 worth ~$15.4 mln.
• LII EVP & Chief Financial Officer sold 2,808 shares at $282.14 - $282.49 worth ~$792K.
• NVEC President and CEO sold 20,000 shares at $87.17 worth ~$1.7 mln.
• OLED Director sold 15,000 shares at $136.61 - $137.24 worth ~$2.1 mln.
• ORLY EV Chairman of the Board sold 1,000 shares at ~$950.4487 worth ~$950K.
• POOL General Counsel/Secretary sold 2,333 shares at $352.00 worth ~$821K.
• SOFI Chief Technology Officer sold 200,000 shares at $5.46 - $5.475 worth ~$1.1 mln.
• UFPT Chief Financial Officer sold 7,354 shares at $142.00 - $142.50 worth ~$1.0 mln.
• WW 10% owner sold 14,818,300 shares at ~$7.15 worth ~$105.95 mln.

=Corcept Therapeutics (CORT) reported earnings on Tue 1 Aug 2017 (a/h)

• #15 on 7/31 (day before)

Corcept reported $35.6 million in sales and adjusted income of 13 cents per share, up a respective 80% and 333% vs. the year-earlier period. Analysts had called for $32.5 million in sales. Adjusted income expectations were not immediately available. Income per share of 10 cents beat analysts' views for 7 cents.

Corcept is continuing to enroll a Phase 2 trial for a drug to treat Cushing's syndrome, which results when the body is exposed to high levels of the hormone cortisol for a long time. Symptoms include abdominal obesity, high blood pressure, stretch marks, weak muscles and bones, and acne.

It also has two cortisol modulators entering Phase 1 trials in the near future. One will be combined with Xtandi, a drug Pfizer (PFE) acquired when it bought Medivation last year, in a population of patients with prostate cancer.

Enrollment is also ongoing in a Phase 1/Phase 2 trial of a drug combined with Celgene's (CELG) Abraxane to treat patients with solid-tumor cancers.